Roche and Blueprint Medicines have signed a global licensing and collaboration deal worth up to $1.7bn for the latter's pralsetinib, an investigational treatment for RET-altered cancers.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,